Epigral Ltd Sees Major Profit Boost in Q3 Earnings Report

Integrated chemical manufacturer Epigral Ltd reported a significant increase in quarterly profit, reaching Rs 81 crore. The revenue rose 32% compared to the previous year, with sales driven by derivatives and specialty business. Capacity utilization was at 83%, while expansions at the Dahej plant were announced.

Epigral Ltd, an integrated chemical manufacturer, has announced a substantial rise in its quarterly profits, reporting Rs 81 crore for the September quarter.

This marks more than a two-fold increase compared to the Rs 38 crore profit in the same period last year. The company's revenue also climbed by 32%, reaching Rs 632 crore from Rs 479 crore.

Growth in sales volume by 6% year-on-year was fuelled by derivatives and specialty business, with capacity utilization at 83%. Despite realization drops in most products, notable capacity expansions are planned for their Dahej plant.

(With inputs from agencies.)